感染疾病药物市场规模、份额和成长分析（按类型、治疗方法和地区划分）—2026-2033年产业预测

预计到 2024 年，感染疾病治疗市场规模将达到 1,249.3 亿美元，到 2025 年将达到 1,302.1 亿美元，到 2033 年将达到 1,813.9 亿美元，在预测期（2026-2033 年）内，复合年增长率为 4.23%。

由病毒和细菌等多种病原体引起的感染疾病对全球医疗保健环境构成重大挑战。儘管诊断技术、治疗方法、卫生习惯、疫苗接种和抗菌疗法的进步已降低了死亡率，但这些疾病的持续发生仍对全球健康状况造成严重影响。由于感染率上升、早期诊断意识增强以及公共和私营部门研究经费的增加，感染疾病治疗市场预计将显着增长。然而，先进治疗方法的高昂费用给患者带来了沉重的经济负担，限制了市场成长。此外，人们对学名药的偏好日益增长，也阻碍了品牌药在该领域的广泛应用。

感染疾病治疗市场成长要素

感染疾病药物市场的成长主要得益于旨在提高治疗方案可及性和有效性的投资增加。提高大众对现有治疗方法和准确诊断重要性的认识也是推动市场成长的因素。此外，专注于开发创新药物疗法的临床试验研究激增，预计将进一步促进该市场的扩张。这些因素共同创造了一个充满活力的环境，有利于感染疾病药物领域的进步，最终改善患者的治疗效果和提高治疗能力。

感染疾病治疗市场的限制

由于人们对各种疾病的现有治疗方案缺乏了解，感染疾病治疗市场面临许多挑战。这种认知不足可能导致医疗服务提供者和患者对治疗方法的接受度较低。此外，发展中地区某些感染疾病的报销政策限制进一步阻碍了市场扩张。这些因素共同构成了治疗产业发展的障碍，因为它们导致有效治疗方案的可近性和利用率较低，从而影响新兴和成熟医疗体系中市场的整体发展。

感染疾病治疗药物市场趋势

受印度、非洲和东南亚等发展中地区疟疾发病率上升的推动，感染疾病治疗市场正经历显着成长。这一成长促使领先的製药公司和医疗机构加大研发投入，致力于开发创新治疗方法和预防措施，以对抗感染疾病。公众对公共卫生策略的日益重视以及对有效医疗解决方案的迫切需求，进一步推动了市场扩张。相关人员的合作，以及技术和诊断技术的进步，有望拓展治疗选择，最终为感染疾病防治创造一个稳健的市场环境。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术进步
• 监管环境
• 案例研究

全球感染疾病治疗药物市场规模（按类型和复合年增长率划分）（2026-2033 年）

• HIV
• 肝炎
• 流感
• 结核
• 疟疾
• HPV

全球感染疾病治疗市场规模（依治疗方法和复合年增长率划分）（2026-2033 年）

• 抗生素
• 抗真菌药物
• 抗病毒药物
• 其他的

全球感染疾病治疗市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 诊所

全球感染疾病治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• Gilead Sciences
• GlaxoSmithKline（GSK）
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson（Janssen Pharmaceuticals）
• BioCryst Pharmaceuticals Inc.
• Boehringer Ingelheim GmbH
• AbbVie Inc.
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb（BMS）
• Moderna, Inc.
• Regeneron Pharmaceuticals
• Vertex Pharmaceuticals
• Vir Biotechnology, Inc.
• Eli Lilly and Company
• Amgen Inc.

结论与建议

Infectious Disease Therapeutics Market size was valued at USD 124.93 Billion in 2024 and is poised to grow from USD 130.21 Billion in 2025 to USD 181.39 Billion by 2033, growing at a CAGR of 4.23% during the forecast period (2026-2033).

Infectious diseases pose a substantial challenge to the global healthcare landscape, driven by various agents like viruses and bacteria. Although advances in diagnostics, treatment, hygiene practices, vaccinations, and antimicrobial therapies have curbed mortality rates, the ongoing emergence of these diseases continues to significantly affect health outcomes worldwide. The market for infectious disease therapeutics is poised for considerable expansion, fueled by increasing incidences of infections, heightened awareness regarding early diagnosis, and enhanced research funding from both private and public sectors. Nonetheless, the high costs associated with advanced treatment options place a financial burden on patients, limiting market growth. Additionally, the rising preference for generic medications poses challenges for the uptake of branded therapeutics in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Infectious Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Infectious Disease Therapeutics Market Segments Analysis

Global Infectious Disease Therapeutics Market is segmented by type, treatment, end users and region. Based on type, the market is segmented into HIV, hepatitis, influenza, TB, malaria and HPV. Based on treatment, the market is segmented into antibacterial, antifungal drugs, antiviral drugs and others. Based on end users, the market is segmented into hospitals and clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Infectious Disease Therapeutics Market

The growth of the infectious disease therapeutics market is being driven by a rise in investment aimed at improving the accessibility and effectiveness of treatment options. Enhanced efforts to promote awareness regarding both the treatments available and the importance of accurate diagnosis are also contributing factors. Additionally, a surge in clinical trial research focused on developing innovative drug therapies is expected to further fuel this market's expansion. Collectively, these elements create a dynamic environment that supports advancements in the field of infectious disease therapeutics, ultimately improving patient outcomes and treatment capabilities.

Restraints in the Infectious Disease Therapeutics Market

The infectious disease therapeutics market faces challenges due to a lack of awareness regarding available treatment options for various disorders. This inadequate understanding can lead to low adoption rates of therapies among healthcare providers and patients. Additionally, the limited reimbursement policies for specific infectious diseases in developing regions further hinder market expansion. These factors collectively create obstacles to the growth of the therapeutics sector, as they contribute to decreased accessibility and utilization of effective treatment solutions, ultimately affecting the overall development of the market in both emerging and established healthcare systems.

Market Trends of the Infectious Disease Therapeutics Market

The Infectious Disease Therapeutics market is witnessing significant traction, driven by the rising incidence of malaria in developing regions such as India, Africa, and Southeast Asia. This surge is accompanied by heightened research and development initiatives by leading pharmaceutical companies and healthcare organizations, focusing on innovative treatments and preventive measures against infectious diseases. The growing awareness of public health strategies and the urgent need for effective healthcare solutions further bolster market expansion. Collaboration among stakeholders, coupled with advancements in technology and diagnostics, is expected to enhance therapeutic options, ultimately shaping a robust market environment for infectious disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Infectious Disease Therapeutics Market Size by Type & CAGR (2026-2033)

• Market Overview
• HIV
• Hepatitis
• Influenza
• TB
• Malaria
• HPV

Global Infectious Disease Therapeutics Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Antibacterial
• Antifungal Drugs
• Antiviral Drugs
• Others

Global Infectious Disease Therapeutics Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics

Global Infectious Disease Therapeutics Market Size & CAGR (2026-2033)

• North America (Type, Treatment, End Users)
  • USA
  • Canada
• Europe (Type, Treatment, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen Pharmaceuticals)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (BMS)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vir Biotechnology, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations